Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.42 |
| ▸ | PYGL | P06737 | 4/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365870 | 0.90 | MAPK14 (0.41) | MAPK14SRD5A2SRD5A1PYGLKDM4C | |
| SCHEMBL12365411 | 0.87 | MAPK14 (0.50) | MAPK14SRD5A2SRD5A1KDM4CALDH1A1 | |
| SCHEMBL12365335 | 0.87 | SRD5A2 (0.54) | SRD5A2SRD5A1PYGLALDH1A1TSHR | |
| SCHEMBL12365312 | 0.86 | MAPK14 (0.48) | MAPK14ALDH1A1 | |
| SCHEMBL12365086 | 0.85 | MAPK14 (0.43) | MAPK14SRD5A2SRD5A1KDM4CALDH1A1 | |
| SCHEMBL12365696 | 0.85 | SRD5A2 (0.42) | SRD5A2SRD5A1ALDH1A1TSHRTTR | |
| SCHEMBL12365414 | 0.85 | MAPK14 (0.45) | MAPK14SRD5A2SRD5A1KDM4CALDH1A1 | |
| SCHEMBL2260725 | 0.84 | HTR5A (0.51) | HTR7 | |
| SCHEMBL12365007 | 0.83 | SRD5A2 (0.49) | SRD5A2SRD5A1ALDH1A1TSHRTTR | |
| SCHEMBL12365096 | 0.83 | MAPK14 (0.42) | MAPK14SRD5A2SRD5A1KDM4CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | MAPK14 3304/4885SRD5A2 412/4885SRD5A1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.